Observations on BPC-157 and GHK-Cu Administration During Extended Fasting Windows: A Protocol Review and Some Unexpected Findings
Posted: Mon Mar 02, 2026 3:37 am
Over the past eight months I have been conducting a self-experimentation protocol involving two peptides administered during varying fasting states, and I believe the data and subjective observations I have collected merit discussion here. I will attempt to be as precise as possible, though I recognize this is n=1 and should be interpreted accordingly.
Background: I have been intermittent fasting for approximately three years using a 20:4 window. Approximately fourteen months ago I began incorporating BPC-157 (administered subcutaneously at 250mcg daily) and GHK-Cu (also subcutaneous, 2mg three times weekly) into my protocol. For the first six months I administered both peptides approximately thirty minutes before breaking my fast, largely operating on the assumption that the absence of food-stimulated insulin would create a more favorable hormonal environment for peptide receptor interaction. This assumption, I now believe, was partially incorrect, or at least more complicated than I had appreciated.
The mistake I made, which I suspect others here may be replicating, was conflating the theoretical benefits of fasted-state hormone profiles with the practical reality of peptide stability and endogenous GH pulsatility patterns. There is reasonable mechanistic literature suggesting that GH secretagogues administered during sleep or deep fasting windows show amplified response, and I was extrapolating that logic uncritically to peptides with entirely different mechanisms of action. BPC-157 does not operate through the same pathways as, say, ipamorelin, and treating them equivalently in terms of timing was methodologically sloppy on my part.
What I observed during the initial six-month period was what I would characterize as inconsistent absorption. The tissue at injection sites showed variable responses, and my subjective sense of the gastroprotective and systemic anti-inflammatory effects that BPC-157 is documented to produce in animal models (Sikiric et al., 2018, among others in Curr Pharm Des) felt erratic. I cannot quantify this precisely, and I acknowledge that limitation fully.
Approximately eight months ago I restructured the protocol. I began administering BPC-157 roughly ninety minutes into my eating window, not immediately upon breaking the fast but after a modest protein intake of approximately 40 grams. My reasoning was that the mild insulin elevation from that meal might actually facilitate tissue delivery without meaningfully interfering with the peptide's mechanism. GHK-Cu I kept in a semi-fasted window, administered approximately two hours before breaking my fast in the morning, as the pro-collagen and antioxidant mechanisms described in Pickart et al. do not appear to be insulin-sensitive in the same way.
The subsequent eight months produced what I would characterize as noticeably more consistent outcomes. The joint and connective tissue recovery observations I was tracking improved in subjective consistency. Sleep architecture, which I monitor via Oura ring data (acknowledging the limitations of consumer-grade wearables), showed modestly improved HRV metrics during this period compared to the prior six months, though confounders are substantial and I would not make strong causal claims.
I want to pose several questions to those with more biochemistry depth than I possess on certain specifics.
First, is there any mechanism-based reason to believe that mild postprandial insulin elevation would materially help or harm BPC-157 bioavailability via subcutaneous administration? The subcutaneous route bypasses first-pass metabolism and I am uncertain whether systemic insulin levels at modest concentrations would influence peptide degradation at the injection site or distribution thereafter.
Second, for those who have experimented with extended fasting windows of 24 hours or longer, did peptide timing relative to the fast appear to matter in ways you could identify? I am curious specifically about whether the autophagic state that emerges after roughly 18 to 24 hours of fasting interacts meaningfully with peptide administration, as there is some theoretical basis for thinking autophagy upregulation could alter receptor expression profiles in ways that modify peptide response.
I am not presenting this as a controlled experiment. The confounders are numerous and I have done my best to list them honestly. But I think the timing question is underexamined in this community and worth serious discussion rather than defaulting to the simplified conventional wisdom of always administering peptides in a fasted state as though that recommendation were universal across all peptide classes.
Background: I have been intermittent fasting for approximately three years using a 20:4 window. Approximately fourteen months ago I began incorporating BPC-157 (administered subcutaneously at 250mcg daily) and GHK-Cu (also subcutaneous, 2mg three times weekly) into my protocol. For the first six months I administered both peptides approximately thirty minutes before breaking my fast, largely operating on the assumption that the absence of food-stimulated insulin would create a more favorable hormonal environment for peptide receptor interaction. This assumption, I now believe, was partially incorrect, or at least more complicated than I had appreciated.
The mistake I made, which I suspect others here may be replicating, was conflating the theoretical benefits of fasted-state hormone profiles with the practical reality of peptide stability and endogenous GH pulsatility patterns. There is reasonable mechanistic literature suggesting that GH secretagogues administered during sleep or deep fasting windows show amplified response, and I was extrapolating that logic uncritically to peptides with entirely different mechanisms of action. BPC-157 does not operate through the same pathways as, say, ipamorelin, and treating them equivalently in terms of timing was methodologically sloppy on my part.
What I observed during the initial six-month period was what I would characterize as inconsistent absorption. The tissue at injection sites showed variable responses, and my subjective sense of the gastroprotective and systemic anti-inflammatory effects that BPC-157 is documented to produce in animal models (Sikiric et al., 2018, among others in Curr Pharm Des) felt erratic. I cannot quantify this precisely, and I acknowledge that limitation fully.
Approximately eight months ago I restructured the protocol. I began administering BPC-157 roughly ninety minutes into my eating window, not immediately upon breaking the fast but after a modest protein intake of approximately 40 grams. My reasoning was that the mild insulin elevation from that meal might actually facilitate tissue delivery without meaningfully interfering with the peptide's mechanism. GHK-Cu I kept in a semi-fasted window, administered approximately two hours before breaking my fast in the morning, as the pro-collagen and antioxidant mechanisms described in Pickart et al. do not appear to be insulin-sensitive in the same way.
The subsequent eight months produced what I would characterize as noticeably more consistent outcomes. The joint and connective tissue recovery observations I was tracking improved in subjective consistency. Sleep architecture, which I monitor via Oura ring data (acknowledging the limitations of consumer-grade wearables), showed modestly improved HRV metrics during this period compared to the prior six months, though confounders are substantial and I would not make strong causal claims.
I want to pose several questions to those with more biochemistry depth than I possess on certain specifics.
First, is there any mechanism-based reason to believe that mild postprandial insulin elevation would materially help or harm BPC-157 bioavailability via subcutaneous administration? The subcutaneous route bypasses first-pass metabolism and I am uncertain whether systemic insulin levels at modest concentrations would influence peptide degradation at the injection site or distribution thereafter.
Second, for those who have experimented with extended fasting windows of 24 hours or longer, did peptide timing relative to the fast appear to matter in ways you could identify? I am curious specifically about whether the autophagic state that emerges after roughly 18 to 24 hours of fasting interacts meaningfully with peptide administration, as there is some theoretical basis for thinking autophagy upregulation could alter receptor expression profiles in ways that modify peptide response.
I am not presenting this as a controlled experiment. The confounders are numerous and I have done my best to list them honestly. But I think the timing question is underexamined in this community and worth serious discussion rather than defaulting to the simplified conventional wisdom of always administering peptides in a fasted state as though that recommendation were universal across all peptide classes.